Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Sotatercept in Newly Diagnosed Pulmonary Arterial Hypertension
2021-000199-12Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sotatercept + background PAH therapy with Placebo + background PAH therapy (2 arms). Primary endpoint: Time to clinical worsening (TTCW). Started Aug 2021; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-000199-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000199-12.